GERON CORP (GERN) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $120.13M; Long-Term Debt, Maturity, Year OneUSD $11.97M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $119.83M; Long-Term Debt, Maturity, Year OneUSD $11.93M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $119.55M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-Term Debt, Maturity, Year OneUSD $3.11M.
GERON CORP Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Debt, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $120.13M | $11.97M | $12.00M | $135.00M | (m) | (m) | (m) | $9.02M | $167.98M | $4.87M | (m) |
| 2026-03-31 | (m) | (m) | $119.83M | $11.93M | $11.96M | $134.97M | (m) | (m) | (m) | $11.93M | $170.78M | $5.17M | (m) |
| 2025-12-31 | (m) | (m) | $119.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $3.11M | $12.34M | $12.34M | $12.37M | $135.31M | $0.00 | (m) | $175.47M | $5.45M | (m) |
| 2025-09-30 | (m) | (m) | $119.26M | $12.72M | $12.72M | $12.76M | $135.63M | (m) | (m) | $6.42M | $180.26M | $5.74M | (m) |
| 2025-06-30 | (m) | (m) | $118.99M | $12.73M | $12.73M | $12.77M | $135.64M | (m) | (m) | $9.59M | $183.47M | $6.01M | (m) |
| 2025-03-31 | (m) | $0.00 | $118.73M | $12.75M | $12.75M | $12.79M | $135.65M | (m) | (m) | $12.75M | $186.69M | $6.27M | (m) |
| 2024-12-31 | (m) | (m) | $118.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $2.19M | $13.08M | $13.08M | $13.08M | $13.12M | $135.93M | (m) | (m) | $6.53M | (m) |
| 2024-09-30 | $71.56M | $71.56M | $12.28M | $89.95M | (m) | (m) | (m) | (m) | (m) | $2.55M | $92.50M | $258.00K | (m) |
| 2024-06-30 | $46.92M | $46.92M | $36.52M | $90.15M | (m) | (m) | (m) | (m) | (m) | $5.29M | $95.43M | $330.00K | (m) |
| 2024-03-31 | $71.53M | $71.53M | $11.22M | $39.26M | (m) | (m) | (m) | (m) | (m) | $53.56M | (m) | $458.00K | (m) |
| 2023-12-31 | (m) | $46.89M | $35.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $46.89M | (m) | (m) | $56.07M | $39.26M | (m) | (m) | (m) | (m) | (m) | (m) | $605.00K | (m) |
| 2023-09-30 | $22.06M | $22.06M | $29.84M | $39.36M | $20.06M | (m) | (m) | (m) | (m) | $1.80M | (m) | $408.00K | (m) |
| 2023-06-30 | $10.84M | $10.84M | $40.80M | $39.28M | $20.03M | (m) | (m) | (m) | (m) | $3.56M | (m) | $483.00K | (m) |
| 2023-03-31 | $0.00 | (m) | $51.40M | $39.19M | $20.01M | (m) | (m) | (m) | (m) | $5.24M | (m) | $556.00K | (m) |
| 2022-12-31 | (m) | $20.95M | $30.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $20.95M | (m) | (m) | $26.84M | $34.16M | (m) | (m) | (m) | (m) | (m) | (m) | $628.00K | (m) |
| 2022-09-30 | $12.96M | $12.96M | $37.80M | $26.41M | $33.86M | (m) | (m) | (m) | (m) | $1.50M | (m) | (m) | (m) |
| 2022-06-30 | $5.16M | $5.16M | $45.26M | $25.88M | $33.50M | (m) | (m) | (m) | (m) | $2.65M | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $50.18M | $25.44M | $33.20M | (m) | (m) | (m) | (m) | $3.53M | (m) | (m) | $776.00K |
| 2021-12-31 | (m) | (m) | $49.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $4.51M | $25.35M | $33.14M | (m) | (m) | (m) | (m) | (m) | (m) | $863.00K |
| 2021-09-30 | (m) | (m) | $34.67M | $5.86M | $19.19M | $18.34M | (m) | (m) | (m) | $796.00K | (m) | (m) | $836.00K |
| 2021-06-30 | (m) | (m) | $34.42M | $5.86M | $19.19M | $18.34M | (m) | (m) | (m) | $1.57M | (m) | (m) | $917.00K |
| 2021-03-31 | (m) | (m) | $24.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $24.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $2.28M | $4.18M | $13.71M | $13.10M | (m) | (m) | (m) | (m) | (m) | $1.06M |
| 2020-09-30 | (m) | (m) | $23.89M | $2.28M | $4.18M | $13.71M | $13.10M | (m) | (m) | $388.00K | (m) | (m) | $1.11M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |